Biotechnology

Mainz Biomed NV

Mainz Biomed collaborates with DoctorBox to launch ColoAlert®

Mainz Biomed NV and OncoVanguard8 Sign Colorectal Cancer Screening Test Memorandum of Understanding

Mainz Biomed NV released FY2025 Q1 earnings on September 26 (EST), actual revenue USD 143.36 K (forecast USD 300 K), actual EPS USD -1.3268 (forecast USD -2.8)

Mainz Biomed NV released FY2025 Semi-Annual earnings on September 26 (EST), actual revenue USD 286.72 K (forecast USD 497 K), actual EPS USD -2.6536

Mainz Biomed NV released FY2025 Q2 earnings on September 26 (EST), actual revenue USD 143.36 K (forecast USD 400 K), actual EPS USD -1.3268 (forecast USD -2.4)

Mainz Biomed Receives Swissmedic Approval for ColoAlert and Set to Launch Commercially in Switzerland

Mainz Biomed NV Receives Public Funds for Pancreatic Cancer Screening Project

Mainz Biomed Receives Public Funding For Pancreatic Cancer Screening Project

Mainz Biomed NV Announces $4 Million Follow-On Offering

Mainz Biomed Launches Enhanced ColoAlert CRC Screening Test

Mainz Biomed NV released FY2024 Q3 earnings on March 31 (EST), actual revenue 186.61 K USD (forecast 250 K USD), actual EPS -3.8567 USD (forecast -4.4 USD)

Mainz Biomed NV released FY2024 Q4 earnings on March 31 (EST), actual revenue 186.61 K USD (forecast 300 K USD), actual EPS -3.8567 USD (forecast -3.6 USD)

Mainz Biomed NV released FY2024 annual earnings on March 31 (EST), actual revenue 893.99 K USD (forecast 1.062 M USD), actual EPS -22.3609 USD (forecast -17.22 USD)

Mainz Biomed NV released FY2024 9 Months earnings on March 31 (EST), actual revenue USD 707.38 K, actual EPS USD -23.5859

Mainz Biomed NV recruits first patient for early detection study 2

HC Wainwright & Co. Downgrades Mainz Biomed Rating to Neutral

Mainz Biomed NV released FY2024 H1 earnings on October 18, 2024 (EST), with actual revenue of 520.77K USD and EPS of -19.7292

Mainz Biomed NV released FY2024 Q2 earnings on October 18 (EST), actual revenue USD 260.39 K (forecast USD 300 K), actual EPS USD -9.8646 (forecast USD -9)

Mainz Biomed NV released FY2024 Q1 earnings on October 18, 2024 (EST), with actual revenue of 260.39K USD (forecast 200K USD) and EPS of -9.8646 (forecast -7.6)

Mainz Biomed NV released FY2022 Q4 earnings on April 9, 2024 (EST), with actual revenue of 193.28K USD and EPS of -21.6

PicoCELA

Highway

Aimei Health Tech

Santech

Trinity Biotech

Vivakor

Syntec Optics

Sable Offshore

Euda Health

Vestand

Adma Biologics

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel Pharma

OpGen

Vertex Pharma

Regeneron Pharma

Alnylam Pharma

Argenx

Beigene

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap